Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global Neurology Clinical Trials Market was valued at around US$ 5.4 billion in 2021. With a projected CAGR of 6.3% for the next ten years, the market is likely to reach a valuation of nearly US$ 10.5 billion by the end of 2032. The neurology clinical trials market is expected to achieve an absolute dollar opportunity growth of US$ 4.8 billion over the forecasted period.
Attributes | Details |
---|---|
Neurology Clinical Trials Market Size (2021A) | US$ 5.4 billion |
Neurology Clinical Trials Market Size (2022E) | US$ 5.7 billion |
Projected Market Value (2032F) | US$ 10.5 billion |
Global Market Growth Rate (2022 to 2032) | 6.3% CAGR |
Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Future Market Insights reveals that Interventional study design led the market for neurology clinical trials. Market revenue through interventional study design grew at 5.6% CAGR from 2017 to 2021. While Huntington’s disease maintained the top Indication in neurology, clinical trials with a growth rate of 5.2% from 2017 to 2021.
The market is likely to grow due to an increase in global neurological disorders. This will drive the market for government spending and collaboration from pharmaceutical companies for the collaboration of new drugs and medication.
According to Lancet medical journal, total disability life adjusted years (DALYs) from, non-communicable neurological disorders like stroke, Alzheimer’s disease, dementia, Parkinson’s disease, and headache disorders increased in India and contributed 82.8% in 2019. Neurological disorders like stroke contributed to the highest share of deaths in India followed by Alzheimer’s. Based on the study, changes in lifestyle habits were a substantial contributor to non-communicable diseases. For instance, high systolic blood pressure, air pollution, and dietary factor contributed to 55.3%, 42.2%, and 28.1% respectively strokes.
The requirement for neurology clinical trials is soaring, but several pharmaceutical companies are leaving the market due to the high cost of clinical trials across therapeutic areas and the high failure rates of clinical trials. Based on the Tufts Center for the Study of Drug Development, CNS drugs take 18% more time to develop when compared to other drugs, and only 6% of drugs are finally approved out of clinical testing. These statistics are discouraging enough for pharmaceutical companies not to invest in neurological clinical trials.
In order to make the transition from Phase I to Phase II trial, companies require data packages to enhance upcoming investments. Few academic and market scientists refuse to share data resulting in a delay in clinical trials.
On the other hand, diagnosis of the central nervous system (CNS) is studied on the basis of symptoms, and signs, and the reasons are varied in different patients within existing diagnostic categories. This makes the identification of the problem difficult.
Moreover, animal models have not shown effective predictive validity and reproducibility. Animal models of CNS disorders are less understood and are not able to recreate the varied neurological human disorders on their model.
With the rise in neurological diseases, such as Alzheimer’s disease and Huntington's disease neuroscience remains a key domain for the majority of investments due to the high societal and monetary burden. Pharma and medical device companies have joined hands to offer better understanding and improved treatment. Moreover, the unprecedented rise in neurological disorders has called for the government to support funding for neurology clinical trials.
Scientists at the University of Sheffield’s Neuroscience Institute and NIHR Sheffield Biomedical Research Centre received funding of US$ 61 Million from the government to bring suitable treatment options for motor neuron disease (MillionD). The funding is expected to change the clinical trials in the coming years.
The government of Australia invested US$ 21.8 Million for the treatment of varied neurological disorders. Around 10 research projects were earmarked in Australia for the treatment of Supranuclear palsy and attempts would be made to reduce fatigue in patients after a stroke. Furthermore, the Clinical Trials Activity Initiative by the Australian Government aims to provide US$ 750 Million over 10 years from 2022 to 23 to Australian researchers in order to increase clinical trials in the country.
The total number of DALYs resulting from neurological disorders was 21 million in the European Union, in 2017 and 41.1 million in WHO European region. A substantial burden will likely catch the attention of neurological clinical trials in Europe.
Development in the healthcare system has extended life expectancy. An increase in the older population has also come up with the burden of non-communicable neurological diseases which is the main driver for spending in neurology clinical trials in Europe.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market for neurology clinical trials in the USA is valued at USA$ 3.7 billion by 2032. Revenue through neurology clinical trials grew at 5.3% CAGR from 2017 to 2021. The USA contributes to a vast number of neurological patients which drives the need for expanding clinical trials. In 2020, 5.8 million Americans suffered from Alzheimer’s disease. This number is projected to triple to 14 million by 2060.
Companies like Biogen and IQVIA have continuously advanced in innovating new drugs and receiving FDA approvals for neurological disorders in America. Government agencies like the National Institute of Neurological Disorders and Stroke fund clinical trials and numerous research programs to reduce the burden of neurological disorders in the USA. The absolute dollar opportunity growth in the USA is expected to be at USA$ 1.8 billion during the forecasted period of 2022 to 2032.
The market for neurology clinical trials in the United Kingdom was valued at USA$ 226 million in 2021. With an absolute dollar opportunity of USA$ 254 million, the market in the country is projected to reach a valuation of USA$ 493 million by 2032. From 2022 to 2032, the market in the United Kingdom is projected to grow at a CAGR of 7.6%.
In Japan, the neurology clinical trials market in Japan was held at USA$ 179 million in 2021. By 2032, the market in Japan is expected to reach a valuation of USA$ 338 million. Growing at a CAGR of 5.7% from 2022 to 2032, the market in the country is likely to gross an absolute dollar opportunity of USA$ 145 million.
The neurology clinical trials market in South Korea is expected to be valued at USA$ 192 million by 2032. With a CAGR of 5.9%, the market in South Korea is expected to gross an absolute dollar opportunity of USA$ 84 million during the forecast period.
Interventional study design dominated the market for neurology clinical trials and accounted for a 5.6% CAGR from 2017 to 2021. It is expected to grow at a rate of 6.5% during the forecasted period. The interventional study design is preferable in most clinical trials due to its safety and cost-effectiveness and acceptability of the Intervention. Interventional study design assists in gauging the direct impact on treatments or prevention of neurological diseases.
Health organizations and pharmaceutical companies are largely aiming at expanding their manufacturing facilities, investing in Research and Development (R&D), and inventing new drugs for the treatment of neurological disorders. The key companies operating in the neurology clinical trials market include Novartis, Covance, Medpace, Charles River Laboratories, Syneous Health, Icon Plc, GlaxoSmithKline, Aurora Healthcare, Biogen, and IQVIA.
Some of the recent developments by key providers of neurology clinical trials are as follows:
Similarly, recent developments related to companies involved in Neurology Clinical Trials have been tracked by the team at Future Market Insights, which is available in the full report.
The global Neurology Clinical Trials market was valued at US$ 5.4 billion in 2021 and US$ 5.7 billion in 2022.
The Neurology Clinical Trials industry is set to witness a high growth rate of 5.4% over the forecast period and is valued at US$ 10.5 by 2032.
Interventional study design maintained its largest share by 5.6% CAGR in 2021 and is expected to grow at 6.5% CAGR during the forecasted period of 2022 to 2032.
Novartis, Covance, Medpace, Charles River Laboratories, Syneous Health, Icon Plc, GlaxoSmithKline, Aurora healthcare, Biogen and IQVIA are the key companies operating in Neurology Clinical Trials Market
Huntington’s disease dominates the market for neurology clinical trials with 5.2% CAGR during 2017 to 2021. Anticipated growth rate of Huntington’s disease is 6.0% during the forecasted period.
The USA, The United Kingdom., China, Japan, and South Korea are expected to drive the most sales growth of neurology clinical trials
The neurology clinical trials market in the USA is valued at US$ 3.7 billion in 2032 and is expected to achieve a growth rate of 6.6% during the forecasted year.
1. Executive Summary | Neurology Clinical Trials Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Investment Feasibility Matrix 3.4. Regulatory Landscape 3.4.1. By Key Regions 3.4.2. By Key Countries 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Phase 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Phase, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Phase, 2022 to 2032 5.3.1. Phase I 5.3.2. Phase II 5.3.3. Phase III 5.3.4. Phase IV 5.4. Y-o-Y Growth Trend Analysis By Phase, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Phase, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Study Design 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Study Design, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Study Design, 2022 to 2032 6.3.1. Interventional 6.3.2. Observational 6.3.3. Expanded Access 6.4. Y-o-Y Growth Trend Analysis By Study Design, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Study Design, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2017 to 2021 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2022 to 2032 7.3.1. Epilepsy 7.3.2. Parkinson's Disease (PD) 7.3.3. Huntington's Disease 7.3.4. Stroke 7.3.5. Traumatic Brain Injury (TBI) 7.3.6. Amyotrophic Lateral Sclerosis (ALS) 7.3.7. Muscle regeneration 7.3.8. Other Indications 7.4. Y-o-Y Growth Trend Analysis By Indication, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By Indication, 2022 to 2032 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia 8.3.6. Oceania 8.3.7. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Phase 9.2.3. By Study Design 9.2.4. By Indication 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Phase 9.3.3. By Study Design 9.3.4. By Indication 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Argentina 10.2.1.4. Rest of Latin America 10.2.2. By Phase 10.2.3. By Study Design 10.2.4. By Indication 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Phase 10.3.3. By Study Design 10.3.4. By Indication 10.4. Key Takeaways 11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. The United Kingdom 11.2.1.5. Spain 11.2.1.6. Russia 11.2.1.7. BENELUX 11.2.1.8. Rest of Europe 11.2.2. By Phase 11.2.3. By Study Design 11.2.4. By Indication 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Phase 11.3.3. By Study Design 11.3.4. By Indication 11.4. Key Takeaways 12. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Phase 12.2.3. By Study Design 12.2.4. By Indication 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Phase 12.3.3. By Study Design 12.3.4. By Indication 12.4. Key Takeaways 13. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Thailand 13.2.1.3. Malaysia 13.2.1.4. Indonesia 13.2.1.5. Rest of South Asia 13.2.2. By Phase 13.2.3. By Study Design 13.2.4. By Indication 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Phase 13.3.3. By Study Design 13.3.4. By Indication 13.4. Key Takeaways 14. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Phase 14.2.3. By Study Design 14.2.4. By Indication 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Phase 14.3.3. By Study Design 14.3.4. By Indication 14.4. Key Takeaways 15. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. Rest of MEA 15.2.2. By Phase 15.2.3. By Study Design 15.2.4. By Indication 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Phase 15.3.3. By Study Design 15.3.4. By Indication 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. The USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2021 16.1.2.1. By Phase 16.1.2.2. By Study Design 16.1.2.3. By Indication 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2021 16.2.2.1. By Phase 16.2.2.2. By Study Design 16.2.2.3. By Indication 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2021 16.3.2.1. By Phase 16.3.2.2. By Study Design 16.3.2.3. By Indication 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2021 16.4.2.1. By Phase 16.4.2.2. By Study Design 16.4.2.3. By Indication 16.5. Argentina 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2021 16.5.2.1. By Phase 16.5.2.2. By Study Design 16.5.2.3. By Indication 16.6. Germany 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2021 16.6.2.1. By Phase 16.6.2.2. By Study Design 16.6.2.3. By Indication 16.7. Italy 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2021 16.7.2.1. By Phase 16.7.2.2. By Study Design 16.7.2.3. By Indication 16.8. France 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2021 16.8.2.1. By Phase 16.8.2.2. By Study Design 16.8.2.3. By Indication 16.9. The United Kingdom 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2021 16.9.2.1. By Phase 16.9.2.2. By Study Design 16.9.2.3. By Indication 16.10. Spain 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2021 16.10.2.1. By Phase 16.10.2.2. By Study Design 16.10.2.3. By Indication 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2021 16.11.2.1. By Phase 16.11.2.2. By Study Design 16.11.2.3. By Indication 16.12. BENELUX 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2021 16.12.2.1. By Phase 16.12.2.2. By Study Design 16.12.2.3. By Indication 16.13. China 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2021 16.13.2.1. By Phase 16.13.2.2. By Study Design 16.13.2.3. By Indication 16.14. Japan 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2021 16.14.2.1. By Phase 16.14.2.2. By Study Design 16.14.2.3. By Indication 16.15. South Korea 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2021 16.15.2.1. By Phase 16.15.2.2. By Study Design 16.15.2.3. By Indication 16.16. India 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2021 16.16.2.1. By Phase 16.16.2.2. By Study Design 16.16.2.3. By Indication 16.17. Thailand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2021 16.17.2.1. By Phase 16.17.2.2. By Study Design 16.17.2.3. By Indication 16.18. Malaysia 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2021 16.18.2.1. By Phase 16.18.2.2. By Study Design 16.18.2.3. By Indication 16.19. Indonesia 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2021 16.19.2.1. By Phase 16.19.2.2. By Study Design 16.19.2.3. By Indication 16.20. Australia 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2021 16.20.2.1. By Phase 16.20.2.2. By Study Design 16.20.2.3. By Indication 16.21. New Zealand 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2021 16.21.2.1. By Phase 16.21.2.2. By Study Design 16.21.2.3. By Indication 16.22. GCC Countries 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2021 16.22.2.1. By Phase 16.22.2.2. By Study Design 16.22.2.3. By Indication 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Phase 17.3.3. By Study Design 17.3.4. By Indication 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. IQVIA 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region) 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.1.5.2. Product Strategy 18.1.1.5.3. Channel Strategy 18.1.2. Novartis 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region) 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.2.5.2. Product Strategy 18.1.2.5.3. Channel Strategy 18.1.3. Covance 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region) 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.3.5.2. Product Strategy 18.1.3.5.3. Channel Strategy 18.1.4. Medpace 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region) 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.4.5.2. Product Strategy 18.1.4.5.3. Channel Strategy 18.1.5. Charles River Laboratories 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region) 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.5.5.2. Product Strategy 18.1.5.5.3. Channel Strategy 18.1.6. GlaxoSmithKline 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region) 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.6.5.2. Product Strategy 18.1.6.5.3. Channel Strategy 18.1.7. Aurora Healthcare 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region) 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.7.5.2. Product Strategy 18.1.7.5.3. Channel Strategy 18.1.8. Biogen 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region) 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.8.5.2. Product Strategy 18.1.8.5.3. Channel Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032 Table 2: Global Market Value (US$ Million) Forecast by Phase, 2017 to 2032 Table 3: Global Market Value (US$ Million) Forecast by Study Design, 2017 to 2032 Table 4: Global Market Value (US$ Million) Forecast by Indication, 2017 to 2032 Table 5: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 6: North America Market Value (US$ Million) Forecast by Phase, 2017 to 2032 Table 7: North America Market Value (US$ Million) Forecast by Study Design, 2017 to 2032 Table 8: North America Market Value (US$ Million) Forecast by Indication, 2017 to 2032 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 10: Latin America Market Value (US$ Million) Forecast by Phase, 2017 to 2032 Table 11: Latin America Market Value (US$ Million) Forecast by Study Design, 2017 to 2032 Table 12: Latin America Market Value (US$ Million) Forecast by Indication, 2017 to 2032 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 14: Europe Market Value (US$ Million) Forecast by Phase, 2017 to 2032 Table 15: Europe Market Value (US$ Million) Forecast by Study Design, 2017 to 2032 Table 16: Europe Market Value (US$ Million) Forecast by Indication, 2017 to 2032 Table 17: East Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 18: East Asia Market Value (US$ Million) Forecast by Phase, 2017 to 2032 Table 19: East Asia Market Value (US$ Million) Forecast by Study Design, 2017 to 2032 Table 20: East Asia Market Value (US$ Million) Forecast by Indication, 2017 to 2032 Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 22: South Asia Market Value (US$ Million) Forecast by Phase, 2017 to 2032 Table 23: South Asia Market Value (US$ Million) Forecast by Study Design, 2017 to 2032 Table 24: South Asia Market Value (US$ Million) Forecast by Indication, 2017 to 2032 Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 26: Oceania Market Value (US$ Million) Forecast by Phase, 2017 to 2032 Table 27: Oceania Market Value (US$ Million) Forecast by Study Design, 2017 to 2032 Table 28: Oceania Market Value (US$ Million) Forecast by Indication, 2017 to 2032 Table 29: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 30: MEA Market Value (US$ Million) Forecast by Phase, 2017 to 2032 Table 31: MEA Market Value (US$ Million) Forecast by Study Design, 2017 to 2032 Table 32: MEA Market Value (US$ Million) Forecast by Indication, 2017 to 2032
Figure 1: Global Market Value (US$ million) by Phase, 2022 to 2032 Figure 2: Global Market Value (US$ million) by Study Design, 2022 to 2032 Figure 3: Global Market Value (US$ million) by Indication, 2022 to 2032 Figure 4: Global Market Value (US$ million) by Region, 2022 to 2032 Figure 5: Global Market Value (US$ million) Analysis by Region, 2017 to 2032 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032 Figure 8: Global Market Value (US$ million) Analysis by Phase, 2017 to 2032 Figure 9: Global Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032 Figure 10: Global Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032 Figure 11: Global Market Value (US$ million) Analysis by Study Design, 2017 to 2032 Figure 12: Global Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032 Figure 13: Global Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032 Figure 14: Global Market Value (US$ million) Analysis by Indication, 2017 to 2032 Figure 15: Global Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 16: Global Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 17: Global Market Attractiveness by Phase, 2022 to 2032 Figure 18: Global Market Attractiveness by Study Design, 2022 to 2032 Figure 19: Global Market Attractiveness by Indication, 2022 to 2032 Figure 20: Global Market Attractiveness by Region, 2022 to 2032 Figure 21: North America Market Value (US$ million) by Phase, 2022 to 2032 Figure 22: North America Market Value (US$ million) by Study Design, 2022 to 2032 Figure 23: North America Market Value (US$ million) by Indication, 2022 to 2032 Figure 24: North America Market Value (US$ million) by Country, 2022 to 2032 Figure 25: North America Market Value (US$ million) Analysis by Country, 2017 to 2032 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 28: North America Market Value (US$ million) Analysis by Phase, 2017 to 2032 Figure 29: North America Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032 Figure 30: North America Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032 Figure 31: North America Market Value (US$ million) Analysis by Study Design, 2017 to 2032 Figure 32: North America Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032 Figure 33: North America Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032 Figure 34: North America Market Value (US$ million) Analysis by Indication, 2017 to 2032 Figure 35: North America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 36: North America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 37: North America Market Attractiveness by Phase, 2022 to 2032 Figure 38: North America Market Attractiveness by Study Design, 2022 to 2032 Figure 39: North America Market Attractiveness by Indication, 2022 to 2032 Figure 40: North America Market Attractiveness by Country, 2022 to 2032 Figure 41: Latin America Market Value (US$ million) by Phase, 2022 to 2032 Figure 42: Latin America Market Value (US$ million) by Study Design, 2022 to 2032 Figure 43: Latin America Market Value (US$ million) by Indication, 2022 to 2032 Figure 44: Latin America Market Value (US$ million) by Country, 2022 to 2032 Figure 45: Latin America Market Value (US$ million) Analysis by Country, 2017 to 2032 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 48: Latin America Market Value (US$ million) Analysis by Phase, 2017 to 2032 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032 Figure 51: Latin America Market Value (US$ million) Analysis by Study Design, 2017 to 2032 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032 Figure 54: Latin America Market Value (US$ million) Analysis by Indication, 2017 to 2032 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 57: Latin America Market Attractiveness by Phase, 2022 to 2032 Figure 58: Latin America Market Attractiveness by Study Design, 2022 to 2032 Figure 59: Latin America Market Attractiveness by Indication, 2022 to 2032 Figure 60: Latin America Market Attractiveness by Country, 2022 to 2032 Figure 61: Europe Market Value (US$ million) by Phase, 2022 to 2032 Figure 62: Europe Market Value (US$ million) by Study Design, 2022 to 2032 Figure 63: Europe Market Value (US$ million) by Indication, 2022 to 2032 Figure 64: Europe Market Value (US$ million) by Country, 2022 to 2032 Figure 65: Europe Market Value (US$ million) Analysis by Country, 2017 to 2032 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 68: Europe Market Value (US$ million) Analysis by Phase, 2017 to 2032 Figure 69: Europe Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032 Figure 71: Europe Market Value (US$ million) Analysis by Study Design, 2017 to 2032 Figure 72: Europe Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032 Figure 74: Europe Market Value (US$ million) Analysis by Indication, 2017 to 2032 Figure 75: Europe Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 77: Europe Market Attractiveness by Phase, 2022 to 2032 Figure 78: Europe Market Attractiveness by Study Design, 2022 to 2032 Figure 79: Europe Market Attractiveness by Indication, 2022 to 2032 Figure 80: Europe Market Attractiveness by Country, 2022 to 2032 Figure 81: East Asia Market Value (US$ million) by Phase, 2022 to 2032 Figure 82: East Asia Market Value (US$ million) by Study Design, 2022 to 2032 Figure 83: East Asia Market Value (US$ million) by Indication, 2022 to 2032 Figure 84: East Asia Market Value (US$ million) by Country, 2022 to 2032 Figure 85: East Asia Market Value (US$ million) Analysis by Country, 2017 to 2032 Figure 86: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 88: East Asia Market Value (US$ million) Analysis by Phase, 2017 to 2032 Figure 89: East Asia Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032 Figure 90: East Asia Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032 Figure 91: East Asia Market Value (US$ million) Analysis by Study Design, 2017 to 2032 Figure 92: East Asia Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032 Figure 93: East Asia Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032 Figure 94: East Asia Market Value (US$ million) Analysis by Indication, 2017 to 2032 Figure 95: East Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 97: East Asia Market Attractiveness by Phase, 2022 to 2032 Figure 98: East Asia Market Attractiveness by Study Design, 2022 to 2032 Figure 99: East Asia Market Attractiveness by Indication, 2022 to 2032 Figure 100: East Asia Market Attractiveness by Country, 2022 to 2032 Figure 101: South Asia Market Value (US$ million) by Phase, 2022 to 2032 Figure 102: South Asia Market Value (US$ million) by Study Design, 2022 to 2032 Figure 103: South Asia Market Value (US$ million) by Indication, 2022 to 2032 Figure 104: South Asia Market Value (US$ million) by Country, 2022 to 2032 Figure 105: South Asia Market Value (US$ million) Analysis by Country, 2017 to 2032 Figure 106: South Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 107: South Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 108: South Asia Market Value (US$ million) Analysis by Phase, 2017 to 2032 Figure 109: South Asia Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032 Figure 110: South Asia Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032 Figure 111: South Asia Market Value (US$ million) Analysis by Study Design, 2017 to 2032 Figure 112: South Asia Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032 Figure 113: South Asia Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032 Figure 114: South Asia Market Value (US$ million) Analysis by Indication, 2017 to 2032 Figure 115: South Asia Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 116: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 117: South Asia Market Attractiveness by Phase, 2022 to 2032 Figure 118: South Asia Market Attractiveness by Study Design, 2022 to 2032 Figure 119: South Asia Market Attractiveness by Indication, 2022 to 2032 Figure 120: South Asia Market Attractiveness by Country, 2022 to 2032 Figure 121: Oceania Market Value (US$ million) by Phase, 2022 to 2032 Figure 122: Oceania Market Value (US$ million) by Study Design, 2022 to 2032 Figure 123: Oceania Market Value (US$ million) by Indication, 2022 to 2032 Figure 124: Oceania Market Value (US$ million) by Country, 2022 to 2032 Figure 125: Oceania Market Value (US$ million) Analysis by Country, 2017 to 2032 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 128: Oceania Market Value (US$ million) Analysis by Phase, 2017 to 2032 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032 Figure 131: Oceania Market Value (US$ million) Analysis by Study Design, 2017 to 2032 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032 Figure 134: Oceania Market Value (US$ million) Analysis by Indication, 2017 to 2032 Figure 135: Oceania Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 137: Oceania Market Attractiveness by Phase, 2022 to 2032 Figure 138: Oceania Market Attractiveness by Study Design, 2022 to 2032 Figure 139: Oceania Market Attractiveness by Indication, 2022 to 2032 Figure 140: Oceania Market Attractiveness by Country, 2022 to 2032 Figure 141: MEA Market Value (US$ million) by Phase, 2022 to 2032 Figure 142: MEA Market Value (US$ million) by Study Design, 2022 to 2032 Figure 143: MEA Market Value (US$ million) by Indication, 2022 to 2032 Figure 144: MEA Market Value (US$ million) by Country, 2022 to 2032 Figure 145: MEA Market Value (US$ million) Analysis by Country, 2017 to 2032 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 148: MEA Market Value (US$ million) Analysis by Phase, 2017 to 2032 Figure 149: MEA Market Value Share (%) and BPS Analysis by Phase, 2022 to 2032 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Phase, 2022 to 2032 Figure 151: MEA Market Value (US$ million) Analysis by Study Design, 2017 to 2032 Figure 152: MEA Market Value Share (%) and BPS Analysis by Study Design, 2022 to 2032 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Study Design, 2022 to 2032 Figure 154: MEA Market Value (US$ million) Analysis by Indication, 2017 to 2032 Figure 155: MEA Market Value Share (%) and BPS Analysis by Indication, 2022 to 2032 Figure 156: MEA Market Y-o-Y Growth (%) Projections by Indication, 2022 to 2032 Figure 157: MEA Market Attractiveness by Phase, 2022 to 2032 Figure 158: MEA Market Attractiveness by Study Design, 2022 to 2032 Figure 159: MEA Market Attractiveness by Indication, 2022 to 2032 Figure 160: MEA Market Attractiveness by Country, 2022 to 2032
Recommendations
Explore Healthcare Insights
View Reports